Summary

Overview
The global diabetic nephropathy market reached US$ 205 million in 2023 and is expected to reach US$ 332 million by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.
Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function that occurs in individuals with diabetes mellitus. It is the leading cause of chronic kidney disease and end-stage renal disease globally.
Diabetic nephropathy develops slowly over many years as high blood glucose levels damage the blood vessels and filters in the kidneys. This can eventually lead to kidney failure, also known as end-stage renal disease (ESRD), which requires dialysis or a kidney transplant. Early detection and management of diabetes, blood pressure, and other risk factors can help prevent or delay the onset and progression of diabetic kidney disease.
Market Dynamics: Drivers
Rising prevalence of diabetic population
The demand for the global diabetic nephropathy market is driven by multiple factors. The increasing prevalence of diabetes, both type 1 and type 2, is a major driver of the diabetic nephropathy market. Diabetes is one of the leading causes of chronic kidney disease (CKD).
The Atlas of the International DM Federation estimated that 537 million adults (20–79 years) will be living with DM in 2022, and this number could increase to 643 million by 2030 and 781 million by 2045. More than 40% of diabetic patients suffer from kidney-related complications, with many progressing to end-stage renal disease requiring dialysis or kidney transplantation.
Moreover, government initiatives such as awareness programs and ongoing clinical trials in the development of treatment for diabetic nephropathy would propel this market growth. For instance, in November 2023, The International Medical Center in Jeddah organized a two-day diabetes awareness campaign, coinciding with World Diabetes Day. The campaign focused on raising awareness of diabetes and the health risks associated with it through educating the public about the different types of diabetes, one of the most widespread diseases in the world, clarifying its root causes and the possible health complications associated with it, such as diabetic foot, diabetic retinopathy, diabetic nephropathy, dental problems, and others.
Also, in February 2023, Bayer announced the European Commission approved a label extension for Kerendia (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D.
Restraints
Factors such as the high cost of the treatment, stringent regulatory approvals, lack of skilled professionals, lack of awareness & diagnosis, and availability of limited treatment options are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global diabetic nephropathy market is segmented based on type, treatment, end-user, and region.
The angiotensin-converting enzyme inhibitor segment accounted for approximately 54.3% of the global diabetic nephropathy market share
The angiotensin-converting enzyme inhibitor segment is expected to hold the largest market share over the forecast period. ACE inhibitors are first-line treatments for diabetic nephropathy to help manage blood pressure in those with diabetes. ACE inhibitors are a class of medications that block the activity of the angiotensin-converting enzyme, which is a key component of the renin-angiotensin-aldosterone system (RAAS). This system is heavily involved in the pathogenesis of diabetic nephropathy.
Moreover, major players more focused on clinical trials and ongoing research studies in the treatment of diabetic nephropathy would propel this market growth. For instance, in June 2023, Bayer announced the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The study's primary objective is to demonstrate the superiority of finerenone over placebo in reducing urine albumin to creatinine ratio (UACR) over 6 months.
Similarly, in January 2024, a Scientific Reports research publication stated that the RENAAL study showed that the ACE inhibitor losartan reduced the risk of doubling serum creatinine, end-stage renal disease, and death by 16% compared to placebo in patients with type 2 diabetes and nephropathy.
Geographical Analysis
North America accounted for approximately 42.4% of the global diabetic nephropathy market share
North America region is expected to hold the largest market share over the forecast period rising prevalence of diabetic kidney diseases in this region, around 40% of people with diabetes could eventually develop diabetic kidney disease, (diabetic nephropathy). kidney failure leading cause in the UK– with around 20 percent of people starting dialysis in the UK.
Diabetic nephropathy is a serious complication that affects around 1 in 3 adults with diabetes in the United States. In 2023, Kidney diseases are one of the leading causes of death in the United States with approximately 37 million, or 1 in 7 Americans having chronic kidney disease (CKD). In 2023, the IDF Diabetes Atlas reported that approximately 30 to 40% of people living with diabetes develop CKD in the U.S.
Moreover, major players' presence in this region, partnerships & collaborations, and a rising number of clinical trials would drive this market growth. For instance, in May 2024, Scarborough Health Network (SHN) held an event celebrating the official launch of a new kidney disease clinic in partnership with University Health Network (UHN). SHN’s Regional Nephrology Program cares for more than 6,000 patients annually and is one of Ontario's 27 Regional Multi-Care Kidney Clinics (MCKC).
Also, in November 2023, ProKidney announced positive interim data from the RMCL-002 phase 2 clinical trial of renal autologous cell therapy (REACT) for diabetic CKD. Updated positive interim Phase 2 data demonstrate REACT's potential efficacy in preserving kidney function in moderate and high-risk diabetic CKD patients.
In addition, key players' innovative launches for the treatment of diabetes nephropathy and well-established healthcare infrastructure help to propel this market growth. For instance, in December 2022, Journey Biosciences launched NaviDKD for people with diabetes to predict long-term kidney complications. NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
Market Segmentation
By Type
• Type-1 Diabetes
• Type-2 Diabetes
By Treatment
• Drug Class
o Angiotensin Converting Enzyme (ACE) Inhibitor
o Angiotensin Receptor Blockers (ARBs)
o Diuretics
o Calcium Channel Blockers (CCBs)
o Renin Inhibitors
o Others
• Renal Replacement Therapies
o Dialysis
o Kidney Transplantation
By End-user
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the diabetic nephropathy market include Novartis AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., Sanofi, AstraZeneca, AbbVie Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, and GSK plc among others.
Key Developments
 In May 2024, Novo Nordisk's (NOVOb.CO), opens a new tab Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke, and death, according to detailed results from a late-stage trial.
 In September 2023, Boehringer Ingelheim and Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
 In June 2022, Mitsubishi Tanabe Pharma Corporation announced that has acquired approval for partial changes to CANAGLU Tablets 100mg (CANAGLU) for the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus.
Why Purchase the Report?
• To visualize the global diabetic nephropathy market segmentation based on type, treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global diabetic nephropathy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global diabetic nephropathy market report would provide approximately 62 tables, 59 figures, and 185 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Diabetic Population
4.1.1.2. Technological Advancements in Diagnosis Techniques
4.1.1.3. Increased Clinical Studies and Government Initiatives
4.1.2. Restraints
4.1.2.1. The High Cost of Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Type-1 Diabetes*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Type-2 Diabetes
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Drug Class*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Angiotensin Converting Enzyme (ACE) Inhibitor
7.2.4. Angiotensin Receptor Blockers (ARBs)
7.2.5. Diuretics
7.2.6. Calcium Channel Blockers (CCBs)
7.2.7. Renin Inhibitors
7.2.8. Others
7.3. Renal Replacement Therapies
7.3.1. Dialysis
7.3.2. Kidney Transplantation
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals & Clinics *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Home Care
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Novartis AG *
11.1.1. Company Overview
11.1.2. Product Portfolio & Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co., Inc
11.3. Johnson & Johnson Services, Inc
11.4. Sanofi
11.5. AstraZeneca
11.6. AbbVie Inc
11.7. Eli Lilly and Company
11.8. Boehringer Ingelheim International GmbH
11.9. Bristol Myers Squibb
11.10. GSK plc
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us